Siri Goli, Mosallaei Meysam, Ehtesham Naeim, Rahimi Hasan, Mazarei Madineh, Nasrollahzadeh Sabet Mehrdad, Behroozi Javad
Department of Internal Medicine, Amir-Alam Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Department of Genetics and Advanced Medical Technology, Faculty of Medicine, AJA University of Medical Sciences, Tehran, Iran.
Adv Biomed Res. 2023 Jun 30;12:174. doi: 10.4103/abr.abr_396_22. eCollection 2023.
Several case-control studies have suggested that global and loci-specific deoxyribonucleic acid (DNA) methylation in peripheral blood mononuclear cells (PBMCs) of DNA might be potential biomarkers of cancer diagnosis and prognosis. In this study, for the first time, we intended to assess the diagnostic power of the methylation level of tumor suppressor candidate 3 () gene promoter in patients with colorectal cancer (CRC).
In the current study, we quantitatively assessed the promoter methylation level of in PBMCs of 70 CRC cases and 75 non-cancerous subjects via methylation quantification of endonuclease-resistant DNA (MethyQESD) method.
The methylation level of the was meaningfully higher in CRC cases than in non-CRC subjects (43.55 ± 21.80% vs. 16.07 ± 13.63%, respectively; < 0.001). The sensitivity and specificity of this gene for the detection of CRC were 88.6% and 76.0%, respectively. The receiver operating characteristic (ROC) curve examination discovered an area under the curve (AUC) of 0.880, representing a very high accuracy of the methylation marker in distinguishing CRC subjects from healthy individuals. However, there was no substantial diversity in methylation level between various CRC stages (: 0.088).
For CRC screening, PBMCs are a reliable source for DNA methylation analysis and promoter methylation can be utilized as a hopeful biomarker for early and non-invasive diagnosis of CRC.
多项病例对照研究表明，外周血单个核细胞（PBMCs）中DNA的整体和位点特异性脱氧核糖核酸（DNA）甲基化可能是癌症诊断和预后的潜在生物标志物。在本研究中，我们首次旨在评估肿瘤抑制候选基因3（）启动子甲基化水平在结直肠癌（CRC）患者中的诊断能力。
在本研究中，我们通过耐核酸酶DNA甲基化定量（MethyQESD）方法定量评估了70例CRC病例和75例非癌受试者PBMCs中该基因启动子的甲基化水平。
CRC病例中该基因的甲基化水平显著高于非CRC受试者（分别为43.55±21.80%和16.07±13.63%；<0.001）。该基因检测CRC的敏感性和特异性分别为88.6%和76.0%。受试者工作特征（ROC）曲线分析发现曲线下面积（AUC）为0.880，表明该基因甲基化标志物在区分CRC受试者与健康个体方面具有很高的准确性。然而，不同CRC阶段之间的甲基化水平没有显著差异（：0.088）。
对于CRC筛查，PBMCs是DNA甲基化分析的可靠来源，该基因启动子甲基化可作为CRC早期和非侵入性诊断的有希望的生物标志物。
